Business
Alkermes to Present Data on Nemvaleukin Alfa at the Society of Gynecologic Oncology 2022 Annual Meeting on Women's Cancer
- New Ovarian Cancer Data From ARTISTRY-1 Clinical Trial to be Featured in Oral Plenary Session - DUBLIN, March 1, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq:
About this update from Alkermes Plc
[{"type":"text","content":"- New Ovarian Cancer Data From ARTISTRY-1 Clinical Trial to be Featured in Oral Plenary Session -\n\n\nDUBLIN, March 1, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present data related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women's Cancer, taking place March 18-21, 2022. New data in patients with platinum-resistant ovarian cancer from ARTISTRY-1, a phase 1/2 study evaluating the safety, tolerability and efficacy of intravenously administered (IV) nemvaleukin as a monotherapy and in combination with pembrolizumab (KEYTRUDA®), will be presented in an oral plenary session. In addition, a trial-in-progress poster from the ongoing ARTISTRY-7 global phase 3 study will be presented. ARTISTRY-7 is evaluating the anti-tumor activity and safety of IV nemvaleukin in combination with pembrolizumab compared to investigator's choice chemotherapy, in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. \nDetails of the presentations are as follows:\nOral Presentation Title: Clinical Outcomes of Ovarian Cancer Patients Treated with the Novel Engineered Cytokine Nemvaleukin Alfa in Combination with the PD-1 Inhibitor Pembrolizumab: Recent Data from ARTISTRY-1 Presenter: Ira Winer, M.D., Ph.D., Associate Professor, Division of Gynecologic Oncology, Wayne State University and Barbara Ann Karmanos Cancer Institute Presentation Date/Time: The oral presentation is scheduled to occur on March 19, 2022 during the Scientific Plenary III session (11:00 a.m. – 12:15 p.m. MST). \nPoster Presentation Poster Number: 326 Title: ARTISTRY-7: A Phase 3, Multicenter Study of Nemvaleukin Alfa, a Novel Engineered Cytokine, in Combination With Pembrolizumab Versus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Presenter: Thomas J. Herzog, M.D., Professor of Obstetrics & Gynecology, Deputy Director, University of Cincinnati Cancer Institute Presentation Date: The poster will be available for on-site and virtual viewing beginning March 18, 2022.\nAbout Nemvaleukin Alfa (\"nemvaleukin\") Nemvaleukin is an investigational, novel, engineered fusion protein comprised of modified...